PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 8 October 1996

The trial utilized a number of clinical sites, including San Francisco General Hospital, Kaiser Permanente (San Francisco), The Rockefeller University, and St. Michaels Hospital in Newark, NJ. Sixty- five patients completed the placebo-controlled study, which evaluated the effect of different doses of Synovir on the patients' weight as a percentage of their baseline weight. Enrollment in the trial was restricted to patients who are infected with HIV and who had lost 10 percent or more of their baseline weight in the preceding six months. Evaluation of the study will include a review of patients' response to a 12-week course of Synovir therapy. The company also noted that approximately 80% of the patients completing the pivotal trial elected to participate in an open label compassionate use follow-on program. "The trial was completed on schedule, and we appreciate the guidance and support of our chief investigators, the participating medical institutions, as well as that of the Food and Drug Administration," said John Jackson, Chairman and CEO of Celgene.

In October 1995, Celgene announced that the Food and Drug Administration had approved the Company's request to authorize expanded access of Synovir, broadening the drug's availability. The expanded access program complemented the Phase II/III clinical trial enrollment. Synovir is the lead product in Celgene's immunotherapeutic program which is developing and evaluating thalidomide and its analogs for possible clinical use in rheumatoid arthritis, inflammatory bowel disease and other major unmet needs.

Celgene Corporation, headquartered in Warren, NJ, uses proprietary expertise in small molecule chemistry to serve the pharmaceutical, agricultural, and allied industries.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties or other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include, but are not limited to, those detailed in the Company's periodic filings with the Securities and Exchange Commission.

SOURCE Celgene Corporation

Copyright (c) 1996/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
961008
PR961008

Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .